A RANDOMIZED COMPARISON OF SIROLIMUS- VERSUS PACLITAXEL-ELUTING STENT FOR TREATMENT OF BIFURCATION LESIONS BY SINGLE STENT AND KISSING BALLOONING: RESULTS OF SINGLE KISS TRIAL

i2 Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 9:30 a.m.-10:30 a.m.

Session Title: Intravascular Diagnostics and Complex Lesions
Abstract Category: PCI - Bifurcations
Presentation Number: 2503-422

Authors: Kenya Nasu, Yuji Oikawa, Tadanori Aizawa, Takahiko Suzuki, Single Kiss Trial Investigators, Toyohashi Heart Center, Toyohashi, AL, Japan, The Cardiovascular Hospital, Minato-ku, AL, Japan

Background: There was few randomized comparison has been carried out comparing different drug-eluting stents for treatment of coronary bifurcation lesions by single stent strategy. The purpose of SINGLE KISS trial was to assess the efficacy of single stent strategy with kissing ballooning after stent implantation using by sirolimus- (SES) and paclitaxel-eluting stents (PES) in patients with bifurcation lesions.

Methods: Inclusion criteria were lesions >75% diameter stenosis within 5mm of a bifurcation in vessels 2.5-4.0mm in diameter in the main branch and >2.25mm in the side branch. Single drug-eluting stent was implanted and kissing ballooning was performed after stenting. Follow-up angiography was scheduled at 9 month and patients were follow-up prospectively for one year.

Results: A total of 839 patients were enrolled at 22 clinical sites. Up to date, 724 (SES group: 382 and PES group: 342) patients completed one year follow-up. The Major Adverse Cardiac Events rates between both groups were similar (Table). There has been no reported stent thrombosis to date.

Conclusions: The results of SINGLE KISS trial demonstrated that single stent strategy with kissing ballooning using by sirolimus- and paclitaxel-eluting stent systems were similar and effective in patients with bifurcation lesions. Complete angiographic and clinical results will be available at the time of presentation.

One-year clinical results

<table>
<thead>
<tr>
<th></th>
<th>SES (n = 382)</th>
<th>PES (n =342)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>0</td>
<td>3 (0.8%)</td>
<td>-</td>
</tr>
<tr>
<td>Myocardial Infarction</td>
<td>1 (0.3%)</td>
<td>1 (0.3%)</td>
<td>-</td>
</tr>
<tr>
<td>TLR</td>
<td>21 (5.8%)</td>
<td>28 (8.1%)</td>
<td>0.18</td>
</tr>
<tr>
<td>TLR for main branch</td>
<td>12/21 (58%)</td>
<td>15/28 (56%)</td>
<td></td>
</tr>
<tr>
<td>TLR for side branch</td>
<td>3/21 (13%)</td>
<td>11/28 (38%)</td>
<td></td>
</tr>
<tr>
<td>TLR for both branches</td>
<td>6/21 (29%)</td>
<td>2/28 (6%)</td>
<td></td>
</tr>
<tr>
<td>TVR</td>
<td>30 (7.7%)</td>
<td>36 (10.6%)</td>
<td>0.24</td>
</tr>
<tr>
<td>SAT/LT</td>
<td>1 (0.3%)</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>